Boston, MA, May 16, 2014 --(PR.com
)-- Ho Man Chan at Novartis will give a presentation on “Global Chromatin Profiling Leads to the Identification of NSD2 Mutations in Pediatric Acute Lymphoblastic Leukemia” at the 5th Cancer Targets & Therapeutics Conference to be held on July 7-8, 2014, in Boston, MA.
Epigenetic dysregulation is an emerging hallmark of cancers. Ho Man Chan will discuss how they’ve developed a high-information-content mass spectrometry approach to profile global histone modifications in human cancers. When applied to 115 lines of the Cancer Cell Line Encyclopedia, this approach identified distinct molecular chromatin signatures. These findings identify NSD2 as a potential therapeutic target for Pediatric Acute Lymphoblastic Leukemia (ALL) and provide a general framework for the functional annotation of cancer epigenomes.
GTCBio's 5th Cancer Targets & Therapeutics Conference will continue to be a premier event for translational researchers, pharmacology experts, preclinical scientists and managers, and those carrying out early phase clinical trials, working to identify and exploit advances in the field in order to deliver products with a meaningful clinical impact. Both cutting-edge researchers and those who guide its commercial development will be on hand to share their knowledge and insights as to how therapeutic cancer targets are identified, and how this research translates into meaningful therapeutics that benefit patients living with cancer.
This conference is part of the larger Novel Cancer Therapeutics Summit, which consists of two co-located parallel conferences:
5th Cancer Targets & Therapeutics Conference
3rd Oncology Partnering & Deal-Making Conference
For more information, please visit www.gtcbio.com